Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 15, 2002
- Kyowa Hakko's Dacarbazine Approved for Hodgkin's Disease
April 15, 2002
- Ain Pharmaciez, Imagawa Yakuhin to Merge This November
April 15, 2002
- Asahi Kasei's Toledomin Shows Steady Growth in Sales
April 15, 2002
- Sugi Pharmacy: Sales Exceed \50 Bil.
April 15, 2002
- BUSINESS NEWS IN BRIEF
April 15, 2002
- OCT NEWS IN BREIF
April 15, 2002
- WEBSITE NEWS
April 15, 2002
- WORLD NEWS IN BRIEF
April 15, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
April 15, 2002
- The 122nd Anniversary Meeting of the Pharmaceutical Society of Japan
April 15, 2002
- Bills for Amended PAL Submitted to the Diet
April 15, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 15, 2002
- Korosho Details 5-year Plan for Policy Evaluation
April 15, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 15, 2002
- Cost Calculation Method Needs Improvements: Budget Committee
April 15, 2002
- Korosho Prepares Decision Tree for Medical Devices
April 15, 2002
- Outline of Relief System for Victims of Tissue Engineering Products Recommended
April 15, 2002
- Terumo Latin America Established in Miami
April 15, 2002
- Plan of Reducing Subsidies to Public Corporations Approved
April 15, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…